UNSPSC 51372008: Homprenorphine

This classification denotes an opioid receptor agonist with the molecular formula C28H37NO4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier SH57250J2D, chemically known as 22-cyclopropyl-7alpha-((r)-1-hydroxy-1-methylpropyl)-6,14-endo-ethenotetrahydrothebaine but generally known as homprenorphine, which bears US NIH Compound Identifier 3084250. European Medicines Agency schedules Homprenorphine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08054MIG.

UNSPSC 51372008 Homprenorphine is a Commodity code that in practice encompasses naloxone, prescription pharmaceuticals, and over-the-counter products procured by state and local health agencies, cooperative purchasing organizations, and public health departments to support community health initiatives, pharmacy benefit programs, and emergency response capabilities. State and local governments buy under this code primarily through competitive bidding (IFB), requests for proposals (RFP), and requests for information (RFI) to establish supply agreements with manufacturers and authorized wholesalers. Issuing bodies include county health departments, state health and human services commissions, and multistate cooperative purchasing alliances that aggregate demand across multiple jurisdictions. The procurement emphasizes compliance with federal manufacturing standards (cGMP, DSCSA, FDA requirements), drug-free workplace certification, E-Verify compliance, and adherence to federal environmental regulations when federal funding is involved.

Recent activity spans Florida, Texas, and Minnesota through cooperative purchasing vehicles. Seminole County, Florida issued IFB 60459723LAS (due July 26, 2023) seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to its Community Health Building, including all shipping costs in vendor proposals and requiring a two-year initial term with one-year renewal option. The Texas Health and Human Services Commission issued RFI HHS0017013 (response due April 3, 2026) to gather market intelligence on direct-to-manufacturer prescription programs that bypass traditional pharmacy benefit managers and wholesalers, targeting vendors with experience in self-insured employer contracting and value-based pricing models. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) issued RFP S1070000015802 (due March 26, 2026) for generic multi-source pharmaceuticals and OTC products distributed through three authorized wholesalers (AmerisourceBergen/Cencora, Cardinal Health, Morris & Dickson), requiring cGMP and DSCSA certification, specific insurance coverages up to $5 million commercial general liability, and pricing competitively weighted at 75 percent of evaluation criteria.